A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma Journal Article

Local Library Link: Find It @ Loyola

Authors: Buchbinder, E. I.; Gunturi, A.; Perritt, J.; Dutcher, J.; Aung, S.; Kaufman, H. L.; Ernstoff, M. S.; Miletello, G. P.; Curti, B. D.; Daniels, G. A.; Patel, S. P.; Kirkwood, J. M.; Hallmeyer, S.; Clark, J. I.; Gonzalez, R; Richart, J. M.; Lutzky, J.; Morse, M. A.; Sullivan, R. J.; McDermott, D. F.
Article Title: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Abstract: BACKGROUND: High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients. However, not all patients respond to immune checkpoint blockade and subsequent therapeutic options need to be explored. METHODS: The PROCLAIM database was queried for patients with metastatic melanoma who had received HD IL-2 after treatment with ipilimumab or without prior ICB. Patient characteristics, toxicity and efficacy were analyzed. RESULTS: A total of 52 metastatic melanoma patients were treated with high dose IL-2 after ipilimumab and 276 patients were treated with high dose IL-2 without prior ICB. The overall response rate in the prior ipilimumab group was 21 % as compared to 12 % in the group that had not received prior ipilimumab. The median overall survival, measured from the initiation of HD IL-2 therapy, was 19.3 months in the prior ipilimumab group and 19.4 months in the no prior ICB group. Toxicities observed on HD IL-2 were relatively equivalent between the groups although there were cases of CTLA4 antibody-induced colitis reported after HD IL-2 treatment and a CTLA4 antibody-induced colitis related death. CONCLUSION: In this retrospective analysis HD IL-2 therapy displayed antitumor activity in melanoma patients who progressed following treatment with ipilimumab. Most HD IL-2 toxicity was not worsened by prior ipilimumab therapy except for one treatment related death from colitis. Care should be taken to avoid reactivation of CTLA4 antibody-induced colitis.
Journal Title: Journal for immunotherapy of cancer
Volume: 4
ISSN: 2051-1426
Publisher: Unknown  
Journal Place: England
Date Published: 2016
Start Page: 52
End Page: 016-0155-8. eCollection 2016
Language: ENG
DOI/URL:

10.1186/s40425-016-0155-8
Notes: LR: 20160925; JID: 101620585; OID: NLM: PMC5028986; OTO: NOTNLM; 2016/04/11 [received]; 2016/08/02 [accepted]; epublish